Revance Therapeutics - 48 Year Dividend Yield History | RVNC

Historical dividend payout and yield for Revance Therapeutics (RVNC) since 1971. The current TTM dividend payout for Revance Therapeutics (RVNC) as of March 21, 2019 is $0.00. The current dividend yield for Revance Therapeutics as of March 21, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.699B $0.004B
Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $118.930B 13.26
Gilead Sciences (GILD) United States $82.398B 10.49
Bio-Techne Corp (TECH) United States $7.497B 50.51